Dr. Ari Molofsky is the candidate applying for the K08 Mentored Clinical Scientist Research Career Development Award. Dr. Molofsky is an MSTP graduate and a Hematopathologist, currently serving as a Clinical Instructor at the University of California San Francisco. This career development proposal has two primary goals. First, Dr. Molofsky outlines a 5-year career development plan that includes mentorship by Dr. Richard Locksley, a multidisciplinary committee structured to provide scientific and career advice, didactic coursework, meetings to promote scientific growth and collaborations, as well as workshops on laboratory management and professional skills. Second, Dr. Molofsky outlines a 5-year research strategy to examine fundamental questions related to allergic immunity in adipose tissue. The worldwide prevalence of obesity and type 2 diabetes has risen dramatically, leading to significant morbidity and mortality. Obesity promotes adipose tissue inflammation and is an early event in the development of insulin resistance and progression to frank diabetes. In contrast, a number of immune cells related to allergic, anti-helminth immunity reside in lean adipose tissue and are protective in models of obesity induced insulin resistance and diabetes. Dr. Molofsky's long-term goal is to elucidate the coordinate regulation, cellular interactions, and individual contributions to metabolic homeostasis of allergic immune cells in metabolic health and disease. The objective of this application is to understand the signals that promote the function of adipose tissue lymphocytes, including innate lymphoid type 2 cells (ILC2), adaptive Th2, and regulatory T cells (Treg), as well as the individual contributions to metabolic homeostasis of each cell type in models of obesity and insulin resistance. The central hypothesis of this proposal is that epithelial cytokines, including IL-33, are actively produced in adipose tissue and coordinately regulate ILC2, Th2, and Treg cells, each of which uniquely contribute to metabolic outcomes. Dr. Molofsky will achieve the objective of this proposal by pursuing three specific aims.
In Aim 1, Dr. Molofsky will test the hypothesis that combinations of epithelial cytokines, including IL-33 and TSLP, promote adipose tissue ILC2 function and cytokine secretion. Using unique ILC2 deficient animals, the precise metabolic impact of ILC2 will be assessed.
In Aim 2, Dr. Molofsky will address the regulation and metabolic contributions of adaptive Th2 cells in adipose tissue, testing the hypothesis that Th2 cells provide a mechanism to increase production of allergic immunity-related cytokines with age and after helminth infection.
In Aim 3, Dr. Molofsky will test the hypothesis that the epithelial cytokine IL 33, along with unknown ILC2 factor(s), coordinately regulate and support adipose tissue Tregs, which are protective in models of obesity-induced insulin resistance. This project is relevant to diabetes research and the mission of the NIH and NIDDK because it has the potential to reveal novel cellular and molecular targets related to allergic immunity that are protective against obesity and the development of diabetes.

Public Health Relevance

Obesity is increasing throughout the world and is associated with adipose tissue inflammation, ultimately leading to systemic inflammation, insulin resistance and progression to type 2 diabetes. In contrast, lean adipose tissue supports distinct anti-inflammatory immune cells associated with an allergic immune response. This proposal addresses the regulation and distinct metabolic contributions of adipose tissue allergic immunity- associated lymphocytes, and the data and reagents generated will provide valuable information to inform future therapies targeting obesity and the progression of diabetes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DK101604-04
Application #
9206155
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK-B)
Program Officer
Spain, Lisa M
Project Start
2014-05-01
Project End
2019-02-28
Budget Start
2017-03-01
Budget End
2018-02-28
Support Year
4
Fiscal Year
2017
Total Cost
$171,792
Indirect Cost
$12,725
Name
University of California San Francisco
Department
Pathology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Ricardo-Gonzalez, Roberto R; Van Dyken, Steven J; Schneider, Christoph et al. (2018) Tissue signals imprint ILC2 identity with anticipatory function. Nat Immunol 19:1093-1099
Vainchtein, Ilia D; Chin, Gregory; Cho, Frances S et al. (2018) Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development. Science 359:1269-1273
Van Dyken, Steven J; Nussbaum, Jesse C; Lee, Jinwoo et al. (2016) A tissue checkpoint regulates type 2 immunity. Nat Immunol 17:1381-1387
Cautivo, Kelly M; Molofsky, Ari B (2016) Regulation of metabolic health and adipose tissue function by group 2 innate lymphoid cells. Eur J Immunol 46:1315-25
Guigas, Bruno; Molofsky, Ari B (2015) A worm of one's own: how helminths modulate host adipose tissue function and metabolism. Trends Parasitol 31:435-41
Lee, Min-Woo; Odegaard, Justin I; Mukundan, Lata et al. (2015) Activated type 2 innate lymphoid cells regulate beige fat biogenesis. Cell 160:74-87
Molofsky, Ari B; Savage, Adam K; Locksley, Richard M (2015) Interleukin-33 in Tissue Homeostasis, Injury, and Inflammation. Immunity 42:1005-19
Molofsky, Ari B; Van Gool, Frédéric; Liang, Hong-Erh et al. (2015) Interleukin-33 and Interferon-? Counter-Regulate Group 2 Innate Lymphoid Cell Activation during Immune Perturbation. Immunity 43:161-74
Van Gool, Frédéric; Molofsky, Ari B; Morar, Malika M et al. (2014) Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. Blood 124:3572-6